Physician profile
Patrick Joseph Mccann
NPI 1487850780
$578,616.45
in general payments reported to CMS, 2019-2025
36 companies · $80K in 2025
The $80K reported for 2025 was more than what 96% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $98K · 2021: $62K · 2022: $61K · 2023: $105K · 2024: $112K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $203K · Travel and Lodging: $48K · Food and Beverage: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Honoraria: $12K · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $203,093.76 |
| Travel and Lodging | $47,976.85 |
| Food and Beverage | $20,139.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,850.00 |
| Honoraria | $12,265.00 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $245,155.51 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Talisman |
| Cvrx, INC. | $153,222.17 | 2019-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $119,430.57 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $23,476.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $11,757.44 | 2022-2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $10,175.27 | 2023-2024 | Inpefa |
| Daxor Corporation | $4,066.33 | 2022-2024 | Bva-100 |
| Ancora Heart, INC. | $2,327.79 | 2023-2025 | Accucinch |
| Boston Scientific Corporation | $1,872.58 | 2019-2025 | Watchman Access System, Watchman Flx, General - Vascular Intervention |
| Medtronic, INC. | $1,028.59 | 2021-2024 | Reveal Linq, Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $976.56 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $669.79 | 2019-2024 | Onpattro |
| Abiomed | $625.49 | 2022-2025 | Impella |
| Pfizer INC. | $585.79 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $440.65 | 2019-2025 | Opsumit, Uptravi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $434.52 | 2021-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.91 | 2019-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $387.55 | 2022-2025 | Optimizer, Optimizer |
| Philips North America LLC | $306.74 | 2022-2023 | |
| Nuwellis, INC. | $242.15 | 2019-2025 | Aquadex Smartflow Console |
| Medtronic Vascular, INC. | $198.00 | 2019-2020 | |
| Scpharmaceuticals INC. | $188.61 | 2023-2025 | |
| Novo Nordisk INC | $144.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $119.87 | 2021-2025 | |
| Nobel Biocare USA | $72.06 | 2021 | |
| Daiichi Sankyo INC. | $58.61 | 2022-2024 | Injectafer |
| Amgen INC. | $51.31 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.86 | 2022-2024 | Eliquis |
| Vifor Pharma, INC. | $39.30 | 2021 | |
| Livanova USA, INC. | $28.35 | 2019 | |
| Recor Medical INC | $24.81 | 2024 | Paradise Renal Denervation System |
| Kestra Medical Technology Services, INC. | $18.01 | 2024 | Assure Wcd |
| Endotronix, INC. | $15.63 | 2021 | |
| Baxter Healthcare | $14.57 | 2025 | Hillrom - Carnation Ambulatory Monitor |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.